Premium
Patient‐centered engagement and symptom/toxicity monitoring in the new era of tumor next‐generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms
Author(s) -
Yanez Betina,
Bouchard Laura C.,
Cella David,
Sosman Jeffrey A.,
Kircher Sheetal M.,
Mohindra Nisha A.,
Cristofanilli Massimo,
Penedo Frank J.
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32030
Subject(s) - medicine , immunotherapy , quality of life (healthcare) , toxicity , patient education , dna sequencing , intensive care medicine , cancer , medical physics , family medicine , nursing , dna , biology , genetics
The growing use of tumor next‐generation sequencing and immunotherapy has led to an increasing need among providers and patients for educational resources and supportive resources for remote and routine symptom and toxicity monitoring. This article describes the development of the OncoTool and OncoPRO platforms, which have been designed to provide easy‐to‐comprehend patient education about advanced cancer treatment options, generate more accurate expectations about tumor next‐generation sequencing and treatment toxicities, and conduct remote and routine monitoring of patient‐reported symptoms, toxicities, and quality of life.